Effects of Glucagon Peptide-1 on Blood Pressure Variability in Diabetic Hypertensive Patients / 天津医药

ABSTRACT

Objective To investigate the role of glucagon peptide-1(GLP-1) in blood pressure variability (BPV) in diabetic hypertensive patients. Methods A total of 120 diabetic hypertensive patients were included in this study. GLP-1 was used for the treatment. The values of body mass index (BMI), fasting blood glucose, glycosylated hemoglobin, creatine and 24-hour ambulatory blood pressure (BP) monitoring were detected before and after treatment with GLP-1 for six months. The clinical indices were compared before and after treatment. Results The values of fasting blood glucose (mmol/L7.12± 0.64 vs 9.19±2.78), glycosylated hemoglobin (%7.00±0.14 vs 8.28±1.32) and BMI (kg/m219.30±3.24 vs 24.5±4.53 ) were de-creased to the normal level after GLP-1 treatment for six months (P<0.05). There were significant decrease in the 24-h sys-tolic BP (mmHg135.02 ± 16.57 vs 139.52 ± 15.60), daytime systolic BP (mmHg132.5 ± 14.6 vs 136.44 ± 14.24), 24-h systolic BP variability (mmHg12.20 ± 1.44 vs 12.73 ± 1.66), daytime systolic BP variability (mmHg11.11 ± 1.48 vs 11.74 ± 1.52 ), and daytime diastolic BP variability (mmHg7.03±1.42 vs 7.43±1.45) after GLP-1 treatment for six months (P<0.05). Conclu-sion GLP-1 can decrease BPV in diabetic hypertensive patients.